anti-Malondialdehyde [MDA], mAb (1F83)
JAI-MMD-030N30 µgCHF 828.00
Immunohistochemical staining of MDA-modified protein in atherosclerotic aorta using anti-MDA, mAb (1F83).
|Product Type||Monoclonal Antibody|
|Immunogen/Antigen||MDA-modified keyhole-lympet hemocyanine.|
|Application||Immunohistochemistry: Recommended concentration is 0.5-1μg/mL on paraffin sections.|
|Specificity||Recognizes MDA-modified proteins (especially DHP-lysine).|
|Purity Detail||Protein A purified.|
|Formulation||Frozen liquid. Contains 10mM PBS, 0.1% NaN3 and 0.5% BSA.|
|Other Product Data||
Click here for Original Manufacturer Product Datasheet
Our product description may differ slightly from the original manufacturers product datasheet.
|Declaration||Manufactured by JaICA.|
|Shipping and Handling|
|Short Term Storage||+4°C|
|Long Term Storage||-20°C|
|Handling Advice||Avoid freeze/thaw cycles.|
|Use/Stability||Stable for at least 3 years after receipt when stored at -20°C.|
|Product Specification Sheet|
Malondialdehyde (MDA) is one of the major aldehyde derive from lipid peroxidation. MDA is highly reactive aldehyde and reacts with lysine residue in protein. The reaction with MDA and lysine residue leads to the formation of numerous numbers of adducts, such as dihydropyridine-lysine (DHP-lysine) type derivative.
- Immunochemical detection of a lipofuscin-like fluorophore derivered from malondialdehyde and lysine: S. Yamada, et al.; J. Lipid Res. 42, 1187 (2001)